Synthon biopharmaceuticals
The ambition of our biopharmaceutical business is to be best-in-class or first-in-class with novel products based on new molecular entities.
Synthon responsibility
Our biopharmaceutical business unit focuses on the development of new biological and chemical entities.
Synthon pipeline
Since the start of Synthon’s biopharmaceutical activities in 2007, we have made significant progress with regard to development of products based on therapeutic proteins.
Synthon licensing and business development
As part of the global Synthon organization, Synthon Biopharmaceuticals is well-positioned to build on the success, infrastructure and organization of the - financially independent, privately held and profitable - parent company.
Synthon event calendar
Synthon Biopharmaceuticals will be present at the following events: